Citadel Advisors
NPCE icon

Citadel Advisors’s Neuropace NPCE Stock Holding History

Citadel Advisors’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-21,900
Closed -$226K – 13630
2025
Q3 		$226K Sell
21,900
-16,700
-43% -$157K ﹤0.01% 11001
2025
Q2 		$430K Buy
38,600
+38,300
+12,767% +$479K ﹤0.01% 8981
2025
Q1 		$3.69K Sell
300
-500
-63% -$6.26K ﹤0.01% 13945
2024
Q4 		$8.95K Buy
800
+700
+700% +$6.09K ﹤0.01% 13666
2024
Q3 		$697 Sell
100
-200
-67% -$1.46K ﹤0.01% 13967
2024
Q2 		$2.27K Sell
300
-7,200
-96% -$72.6K ﹤0.01% 13712
2024
Q1 		$99K Buy
+7,500
New +$107K ﹤0.01% 11371

Other funds holding NPCE

PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Citadel Advisors's NPCE Position: Q1 2026 in Review

Citadel Advisors reduced its Neuropace (NPCE) stake by 34% in Q1 2026, selling an estimated $669K and leaving 87,284 shares worth $1.15M. The position accounts for ﹤0.01% of the portfolio, ranked #7342.

Citadel Advisors first reported a position in NPCE in Q3 2021 and has held it in 11 quarters since. The position peaked at $2.04M in Q4 2025. 113 funds tracked by Wall St. Rank hold NPCE as of Q1 2026.

  • Citadel Advisors held 87,284 shares of Neuropace worth $1.15M as of Q1 2026.
  • Citadel Advisors sold 44,575 Neuropace shares in Q1 2026, an estimated $669K.
  • Neuropace made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #7342 holding.
  • Citadel Advisors first reported a position in Neuropace in Q3 2021 and has held it in 11 quarters since.
  • Citadel Advisors's Neuropace position peaked at $2.04M in Q4 2025.
  • 113 funds tracked by Wall St. Rank held Neuropace as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.